TheraLink™ HER Family Assay Provides Guidance for Directing Molecular Targeted Therapies Lewsiville, TX, May 29, 2013 med fusion and Theranostics Health will introduce the first of the TheraLink™ Assays for use in patients with malignant diseases at the American Society of Clinical Oncology (ASCO) Annual '13 Meeting, held in Chicago, [...]
Lewsiville, TX, May 1, 2013 med fusion, Pathologists Bio-Medical Laboratories (PBM) and Theranostics Health will be introducing the first of Theranostics Health’s TheraLink™ Assays for use in patients with malignant diseases at the upcoming American Society of Clinical Oncology (ASCO) Annual ’13 Meeting, held in Chicago, IL from May 30, [...]
med fusion clin-labs supports “Choosing Wisely®”, an initiative recently announced by the American Society of Clinical Pathology (ASCP), urging physicians and patients to engage in important conversations about some medical tests and procedures that may provide little benefit and in some cases actually harm. “Choosing Wisely” means questioning is it [...]
Based on med fusion's 2012 contribution to Carter BloodCare's community blood supply, we are now considered a Carter BloodCare Bronze Partner. As part of the Premier Partners program, our Bronze status means we have more opportunities for making a difference.
Lewsiville, TX, August 15, 2012 med fusion and Theranostics Health have entered into a Market Development Agreement to validate the clinical utility of Theranostics’ TheraLink™ Assays for use in patients with malignant diseases. The goal of this relationship is to help accelerate advancement of new methods in molecular diagnostics testing [...]
Indianapolis, June 5, 2012 Collaborative relationship designed to help accelerate advancement of new methods in molecular diagnostics testing and personalized predictive treatment Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the establishment of a strategic alliance with med fusion LLC in Lewisville, Texas, that designates the company as a Roche [...]
The cobas® HPV test uncovers disease missed by cytology, providing more information about cancer risk in women with normal cytology (NILM) than pooled hrHPV testing alone. Approximately one in 10 women with normal cytology who were HPV 16+ and/or 18+ actually had high-grade cervical disease that was missed with cytology.1 [...]
November 8, 2010 Dallas Business Journal med fusion has entered a contract with HCA North Texas to provide lab services for more than 30 HCA hospitals, outpatient surgery centers and other facilities in North Texas. "The agreement gives Dallas-based HCA hospitals immediate, local access to hundreds of complex tests performed [...]
Since med fusion began operation in May, the company has recycled approximately 42% of its waste stream. This includes standard items that are recycled including plastic, glass, paper, cardboard, toner cartridges and pallets. In addition to the standard items, med fusion has also been able to recycle other items such [...]
Lewisville, Texas – October 25, 2010 – med fusion, an integrated laboratory reference testing and trial services company, announced today it has entered into an agreement with HCA North Texas to provide local reference laboratory testing services, which are currently sent outside the North Texas community. Dallas-based HCA hospitals will [...]
Keith Laughman, President and CEO of med fusion, spoke at the Washington G-2 Reports 28th Annual Lab Institute 2010 Conference held October 13-15, 2010. To download a PDF of his PowerPoint presentation please click here.
Dallas, Texas – A new company integrating advanced laboratory services and clinical trials services announced it will operate under the name med fusion and will be headquartered in Dallas, Texas. Baylor Health Care System, Texas Oncology PA, Pathologists Biomedical Laboratories LLP and US Oncology have joined to create a [...]